[Obituary] Mother of Lee Gil-ho (Executive Director, Daewon Pharmaceutical) passed away
Predicted impact: Low
Family bereavement notice for an executive; no business impact.
Daewon Pharmaceutical대원제약
003220 · KOSPI · ₩003220 · 대원제약
₩7,730▲ ₩90 (1.18%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −40.95%
- Market cap
- ₩173B
- Enterprise value
- ₩292B
- P/E
- 65.9×
- P/B
- 0.6×
- Dividend yield
- 0.0%
- ROE
- 1.0%
- Net margin
- 0.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−43.5% from the high
₩7,060Today: ₩7,710 – ₩8,110₩13,670
Returns
- 1W−1.7%
- 1M−1.5%
- 3M+3.1%
- 6M−28.9%
- YTD−35.3%
- 1Y−40.9%
- Volume today
- 185,483
- 4.2× the 20-day average
- Traded today
- ₩1.5B
- Listed shares
- 22,427,583
- EPS (12 months)
- ₩117
- Earnings yield 1.5%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+1.2% on Oct 27, 2026. Trading value 4.1× its normal.
- • Foreign investors sold a net ₩255M that day
- • Buzz 63 on JONBUR: heavy trading
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Warming up- BuzzRisingBuzz 63: heavy trading.
- MomentumFlat-1% over the last month; the price is below its 20-day average.
- News impactLow8 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Daewon Pharmaceutical stock overview
Daewon Pharmaceutical (대원제약, KRX: 003220) is listed on KOSPI, in the Biotech & Pharma sector. Daewon Pharmaceutical is a South Korean company that manufactures and sells pharmaceuticals, including prescription drugs and over-the-counter cold medicines, supplying hospitals, clinics and pharmacies in Korea. Its shares closed at ₩7,730 on Oct 27, 2026, up 1.18% on the day, giving it a market value of ₩173B.
Key facts
- Market cap
- ₩173B
- Sector
- Biotech & Pharma
- Latest price change
- +1.18%
- As of
- Oct 27, 2026
- Main business
- Daewon Pharmaceutical is a South Korean company that manufactures and sells pharmaceuticals, including prescription drugs and over-the-counter cold medicines, supplying hospitals, clinics and pharmacies in Korea.
Quick answers about Daewon Pharmaceutical
- What does Daewon Pharmaceutical do?
- Daewon Pharmaceutical is a South Korean company that manufactures and sells pharmaceuticals, including prescription drugs and over-the-counter cold medicines, supplying hospitals, clinics and pharmacies in Korea. It also runs contract manufacturing for other drug companies, exports finished drugs and medical devices overseas, and sells health functional foods. Through its subsidiaries it sells cosmetics, notably SNP mask packs, as well as hearing aids and medical devices in Korea and Southeast Asia.
- What is the market cap of Daewon Pharmaceutical?
- The market capitalisation of Daewon Pharmaceutical was ₩173B at the close on Oct 27, 2026.
- Who are the largest shareholders of Daewon Pharmaceutical?
- According to the latest official filings, the largest reported holders are Fidelity Management & Research Company LLC (9.99%, as of Feb 17, 2025); Fidelity Low-Priced Stock Fund (9.66%, as of Jul 31, 2026); National Pension Service (0.90%, as of Dec 31, 2025).
- When is the next earnings report from Daewon Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Daewon Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Daewon Pharmaceutical?
- Yes. The National Pension Service held 0.90% of Daewon Pharmaceutical shares as of Dec 31, 2025.
Company profile
Daewon Pharmaceutical is a South Korean company that manufactures and sells pharmaceuticals, including prescription drugs and over-the-counter cold medicines, supplying hospitals, clinics and pharmacies in Korea. It also runs contract manufacturing for other drug companies, exports finished drugs and medical devices overseas, and sells health functional foods. Through its subsidiaries it sells cosmetics, notably SNP mask packs, as well as hearing aids and medical devices in Korea and Southeast Asia.
Written by AI from the company's latest annual report.
- Korean name
- 대원제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 백승열, BAEK JONATHAN IN
- Founded
- Aug 1961
- Listed
- Dec 1999
- Listed shares
- 22,427,583
- Fiscal year ends
- Month 12
- Website
- www.daewonpharm.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Daewon Pharmaceutical also hits the accelerator on oral obesity drug development
Predicted impact: Low
Oral obesity drug development updates repeat earlier clinical news; early-stage, no revenue size given.
Daewon Pharmaceutical presents oral platform diabetes and obesity drug clinical data in the US
Predicted impact: Low
Early-stage US research presentation for an oral diabetes drug; no revenue impact yet.
Recent filings
See all- Investor relations (IR) eventSep 15, 2026
- Fair Trade Self-Compliance Program Operation Status (Informational Disclosure)Aug 28, 2026
- Half-year report (Jun 2026)Aug 7, 2026
- Investor relations (IR) eventJun 12, 2026
- Insider shareholding reportJun 10, 2026
Titles in Korean until English translations are added.
Also known as: Daewon Pharmaceutical / 대원제약 / 003220 / KRX:003220
Source: KRX statistical information